338 related articles for article (PubMed ID: 15291677)
1. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.
Zanarini MC; Frankenburg FR; Parachini EA
J Clin Psychiatry; 2004 Jul; 65(7):903-7. PubMed ID: 15291677
[TBL] [Abstract][Full Text] [Related]
2. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.
Corya SA; Perlis RH; Keck PE; Lin DY; Case MG; Williamson DJ; Tohen MF
J Clin Psychiatry; 2006 May; 67(5):798-806. PubMed ID: 16841630
[TBL] [Abstract][Full Text] [Related]
3. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression.
Brown EB; McElroy SL; Keck PE; Deldar A; Adams DH; Tohen M; Williamson DJ
J Clin Psychiatry; 2006 Jul; 67(7):1025-33. PubMed ID: 16889444
[TBL] [Abstract][Full Text] [Related]
4. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.
Trivedi MH; Thase ME; Osuntokun O; Henley DB; Case M; Watson SB; Campbell GM; Corya SA
J Clin Psychiatry; 2009 Mar; 70(3):387-96. PubMed ID: 19284928
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.
Thase ME; Corya SA; Osuntokun O; Case M; Henley DB; Sanger TM; Watson SB; Dubé S
J Clin Psychiatry; 2007 Feb; 68(2):224-36. PubMed ID: 17335320
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
Shelton RC; Williamson DJ; Corya SA; Sanger TM; Van Campen LE; Case M; Briggs SD; Tollefson GD
J Clin Psychiatry; 2005 Oct; 66(10):1289-97. PubMed ID: 16259543
[TBL] [Abstract][Full Text] [Related]
7. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial.
Shi L; Namjoshi MA; Swindle R; Yu X; Risser R; Baker RW; Tohen M
Clin Ther; 2004 Jan; 26(1):125-34. PubMed ID: 14996525
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
Corya SA; Williamson D; Sanger TM; Briggs SD; Case M; Tollefson G
Depress Anxiety; 2006; 23(6):364-72. PubMed ID: 16710853
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M
J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies.
Tohen M; Case M; Trivedi MH; Thase ME; Burke SJ; Durell TM
J Clin Psychiatry; 2010 Apr; 71(4):451-62. PubMed ID: 20361905
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial.
Bozzatello P; Rocca P; Uscinska M; Bellino S
CNS Drugs; 2017 Sep; 31(9):809-819. PubMed ID: 28741044
[TBL] [Abstract][Full Text] [Related]
12. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression.
Keck PE; Corya SA; Altshuler LL; Ketter TA; McElroy SL; Case M; Briggs SD; Tohen M
J Clin Psychiatry; 2005 May; 66(5):611-6. PubMed ID: 15889948
[TBL] [Abstract][Full Text] [Related]
13. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study.
Zanarini MC; Schulz SC; Detke HC; Tanaka Y; Zhao F; Lin D; Deberdt W; Kryzhanovskaya L; Corya S
J Clin Psychiatry; 2011 Oct; 72(10):1353-62. PubMed ID: 21535995
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study.
Zanarini MC; Frankenburg FR
J Clin Psychiatry; 2001 Nov; 62(11):849-54. PubMed ID: 11775043
[TBL] [Abstract][Full Text] [Related]
15. Serotonin transporter polymorphism and fluoxetine effect on impulsiveness and aggression in borderline personality disorder.
Silva H; Iturra P; Solari A; Villarroel J; Jerez S; Vielma W; Montes C; Pumarino L; Roa N
Actas Esp Psiquiatr; 2007; 35(6):387-92. PubMed ID: 17597424
[TBL] [Abstract][Full Text] [Related]
16. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.
Andersen SW; Clemow DB; Corya SA
J Clin Psychiatry; 2005 Nov; 66(11):1468-76. PubMed ID: 16420086
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial.
Detke HC; DelBello MP; Landry J; Usher RW
J Am Acad Child Adolesc Psychiatry; 2015 Mar; 54(3):217-24. PubMed ID: 25721187
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression.
Brown E; Dunner DL; McElroy SL; Keck PE; Adams DH; Degenhardt E; Tohen M; Houston JP
Int J Neuropsychopharmacol; 2009 Jul; 12(6):773-82. PubMed ID: 19079815
[TBL] [Abstract][Full Text] [Related]
19. [Fluoxetine in the treatment of borderline personality disorder].
Silva H; Jerez S; Paredes A; Salvo J; Rentería P; Ramírez A; Montes C
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997; 25(6):391-5. PubMed ID: 9477607
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico.
Tamayo JM; Sutton VK; Mattei MA; Diaz B; Jamal HH; Vieta E; Zarate CA; Fumero I; Tohen M
J Clin Psychopharmacol; 2009 Aug; 29(4):358-61. PubMed ID: 19593175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
